Drugs / KN019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04038970 | Nov 2019 → Jul 2022 | rheumatoid arthritis | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-09-30 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Results 康宁杰瑞KN019治疗类风湿性关节炎Ⅱ期研究达到主要终点 alphamabonc.com ↗
2022年9月30日，中国苏州，康宁杰瑞生物制药（股票代码：9966.HK）宣布，自主研发的重组人 CTLA-4 变体 Fc 融合蛋白KN019治疗甲氨蝶呤（MTX）应答不充分的活动性类风湿关节炎的Ⅱ期临床研究（研究编号：KN019-201）达到主要研究终点。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-09-30 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 康宁杰瑞KN019治疗类风湿性关节炎Ⅱ期研究达到主要终点 alphamabonc.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04038970 ↗ |
| Route | Intravenous | “Solution, intravenous, 5 mg/kg” NCT04038970 ↗ |